EMA Withdrawn: Kolbam (cholic acid) — Retrophin Europe Ltd

View source ↗

Summary

Kolbam (cholic acid) has been withdrawn from the market in the EU by Retrophin Europe Ltd according to EMA records.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inborn Errors of Bile Acid Synthesis
• Metabolic Disorders Related to Bile Acid Metabolism

Drugs mentioned

• Kolbam (cholic acid)

Snippet

Status: Withdrawn. Therapeutic area: Metabolism, Inborn Errors. MAH: Retrophin Europe Ltd. Decision date: 27/03/2020